BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 37839675)

  • 1. Cutaneous Manifestations of Myeloid Neoplasms Exhibit Broad and Divergent Morphologic and Immunophenotypic Features but Share Ancestral Clonal Mutations With Bone Marrow.
    Sadigh S; DeAngelo DJ; Garcia JS; Hasserjian RP; Hergott CB; Lane AA; Lovitch SB; Lucas F; Luskin MR; Morgan EA; Pinkus GS; Pozdnyakova O; Rodig SJ; Shanmugam V; Tsai HK; Winer ES; Zemmour D; Kim AS
    Mod Pathol; 2024 Jan; 37(1):100352. PubMed ID: 37839675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Flow Cytometry Identifies a Spectrum of Maturation in Myeloid Neoplasms Having Plasmacytoid Dendritic Cell Differentiation.
    Hamadeh F; Awadallah A; Meyerson HJ; Beck RC
    Cytometry B Clin Cytom; 2020 Jan; 98(1):43-51. PubMed ID: 30614203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone marrow clonal hematopoiesis is highly prevalent in blastic plasmacytoid dendritic cell neoplasm and frequently sharing a clonal origin in elderly patients.
    Khanlari M; Yin CC; Takahashi K; Lachowiez C; Tang G; Loghavi S; Bah I; Wang W; Konoplev S; Medeiros LJ; Pemmaraju N; Khoury JD; Wang SA
    Leukemia; 2022 May; 36(5):1343-1350. PubMed ID: 35279700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blastic plasmacytoid dendritic cell neoplasm arising from clonal hematopoiesis.
    Suma S; Sakata-Yanagimoto M; Nguyen TB; Hattori K; Sato T; Noguchi M; Nannya Y; Ogawa S; Watanabe R; Fujimoto M; Nakamura N; Kusakabe M; Nishikii H; Kato T; Chiba S
    Int J Hematol; 2018 Oct; 108(4):447-451. PubMed ID: 29705980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic management of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in close interaction with therapeutic considerations.
    Shumilov E; Mazzeo P; Ghandili S; Künstner A; Weidemann S; Banz Y; Ströbel P; Pollak M; Kolloch L; Beltraminelli H; Kerkhoff A; Mikesch JH; Schliemann C; Haase D; Wulf G; Legros M; Lenz G; Feldmeyer L; Pabst T; Witte H; Gebauer N; Bacher U
    Ann Hematol; 2024 May; 103(5):1587-1599. PubMed ID: 38194088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cutaneous presentation preceding acute myeloid leukemia with CD4+/CD56+ expression misdiagnosed as a blastic plasmocytoid dendritic cell neoplasm: A case report.
    Szablewski V; Costes V; Bret C; Dereure O; Yosr H; Alame M; Cacheux V
    J Cutan Pathol; 2018 Aug; 45(8):610-614. PubMed ID: 29660158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cutaneous myeloid dendritic cell dyscrasia: A cutaneous clonal monocytosis associated with chronic myeloproliferative disorders and peripheral blood monocytosis.
    Magro CM; Momtahen S; Verma S; Abraham RM; Friedman C; Nuovo GJ; Tam W
    Ann Diagn Pathol; 2016 Dec; 25():85-91. PubMed ID: 27806853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An Analysis of the Pathologic Features of Blastic Plasmacytoid Dendritic Cell Neoplasm Based on a Comprehensive Literature Database of Cases.
    Ohgami RS; Aung PP; Gru AA; Hussaini M; Singh K; Querfeld C; Yao K; Small C; Gollapudi S; Jaye D; Wang SA; Pullarkat S; George TI
    Arch Pathol Lab Med; 2023 Jul; 147(7):837-846. PubMed ID: 36170615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blastic plasmacytoid dendritic cell neoplasm (BPDCN): a rare entity.
    Lim MS; Lemmert K; Enjeti A
    BMJ Case Rep; 2016 Jan; 2016():. PubMed ID: 26791132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A blastic plasmacytoid dendritic cell neoplasm-like immunophenotype is negatively associated with CEBPA bZIP mutation and predicts unfavorable prognosis in acute myeloid leukemia.
    Song J; Li W; Bai Y; Zhou P; Niu J; Niu X; Liu Y; Liu X; Drokow EK; Sun K; Zhou H
    Ann Hematol; 2024 Feb; 103(2):463-473. PubMed ID: 38183444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coexisting and cooperating mutations in NPM1-mutated acute myeloid leukemia.
    Patel JL; Schumacher JA; Frizzell K; Sorrells S; Shen W; Clayton A; Jattani R; Kelley TW
    Leuk Res; 2017 May; 56():7-12. PubMed ID: 28152414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemical analysis of CD123, CD56 and CD4 for the diagnosis of minimal bone marrow involvement by blastic plasmacytoid dendritic cell neoplasm.
    Hwang K; Park CJ; Jang S; Chi HS; Huh JR; Lee JH; Suh C; Lee KH
    Histopathology; 2013 Apr; 62(5):764-70. PubMed ID: 23470050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Case report: Common clonal origin of concurrent langerhans cell histiocytosis and acute myeloid leukemia.
    Kazama S; Yokoyama K; Ueki T; Kazumoto H; Satomi H; Sumi M; Ito I; Yusa N; Kasajima R; Shimizu E; Yamaguchi R; Imoto S; Miyano S; Tanaka Y; Denda T; Ota Y; Tojo A; Kobayashi H
    Front Oncol; 2022; 12():974307. PubMed ID: 36185232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spectrum of histiocytic neoplasms associated with diverse haematological malignancies bearing the same oncogenic mutation.
    Kemps PG; Hebeda KM; Pals ST; Verdijk RM; Lam KH; Bruggink AH; de Lil HS; Ruiterkamp B; de Heer K; van Laar JA; Valk PJ; Mutsaers P; Levin MD; Hogendoorn PC; van Halteren AG
    J Pathol Clin Res; 2021 Jan; 7(1):10-26. PubMed ID: 32852896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Immunohistochemical evaluation of BCL-2 expression in acute myeloid leukemia, myeloid sarcoma, and blastic plasmacytoid dendritic cell neoplasm].
    Saika W; Kawahara M; Tashiro H; Teramoto Y; Nagai S; Kumode M; Iwasa M; Asai A; Fujishiro A; Nishimura R; Minamiguchi H; Moritani S; Kito K; Andoh A
    Rinsho Ketsueki; 2020; 61(12):1647-1653. PubMed ID: 33441515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunophenotypic and Molecular Features of Acute Myeloid Leukemia with Plasmacytoid Dendritic Cell Differentiation Are Distinct from Blastic Plasmacytoid Dendritic Cell Neoplasm.
    Wang W; Xu J; Khoury JD; Pemmaraju N; Fang H; Miranda RN; Yin CC; Hussein SE; Jia F; Tang Z; Hu S; Konopleva M; Medeiros LJ; Wang SA
    Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutated ZRSR2 and CUL3 accelerate clonal evolution and confer venetoclax resistance via RAS signaling pathway in blastic plasmacytoid dendritic cell neoplasm.
    Fukuchi K; Koyama D; Takada M; Mori H; Hayashi K; Asano N; Sato Y; Fukatsu M; Takano M; Takahashi H; Shirado-Harada K; Kimura S; Yamamoto T; Ikezoe T
    Int J Hematol; 2023 Oct; 118(4):489-493. PubMed ID: 37029861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TET2 mutations, myelodysplastic features, and a distinct immunoprofile characterize blastic plasmacytoid dendritic cell neoplasm in the bone marrow.
    Alayed K; Patel KP; Konoplev S; Singh RR; Routbort MJ; Reddy N; Pemmaraju N; Zhang L; Shaikh AA; Aladily TN; Jain N; Luthra R; Medeiros LJ; Khoury JD
    Am J Hematol; 2013 Dec; 88(12):1055-61. PubMed ID: 23940084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Case of Blastic Plasmacytoid Dendritic Cell Neoplasm with Orbital Tumor as the Initial Symptom.
    Li P; Pang N; Li M; Xie J; Wang Y
    Clin Lab; 2024 Apr; 70(4):. PubMed ID: 38623681
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blastic Plasmacytoid Dendritic Cell Neoplasm: From Origin of the Cell to Targeted Therapies.
    Laribi K; Denizon N; Besançon A; Farhi J; Lemaire P; Sandrini J; Truong C; Ghnaya H; Baugier de Materre A
    Biol Blood Marrow Transplant; 2016 Aug; 22(8):1357-1367. PubMed ID: 27026248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.